Additionally, VIP acts in concert with IL-33 to activate mammalian target of rapamycin (mTOR), which increases glycolysis, potentiates the production of intestinal ILC2 effector cytokines, and increases resistance to high-dose infection with T. muris73. This evidence concerns the gene IL33 and infection.